Exogenous activated protein C inhibits the progression of diabetic nephropathy

Journal of Thrombosis and Haemostasis

Volumn 10, Issue 3, 2012, Pages 337-346

  Gil Bernabe, P ^a   D'Alessandro Gabazza, C N ^a   Toda, M ^a   Boveda Ruiz, D ^a   Miyake, Y ^a   Suzuki, T ^a   Onishi, Y ^a   Morser, J ^b   Gabazza, E C ^a   Takei, Y ^a   Yano, Y ^a  

^a MIE UNIVERSITY   (Japan)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Activated protein C; Diabetes; Glomerulosclerosis

Indexed keywords

ACTIVATED PROTEIN C; COLLAGEN; CONNECTIVE TISSUE GROWTH FACTOR; CREATININE; HYDROXYPROLINE; MONOCYTE CHEMOTACTIC PROTEIN 1; NEPHRIN; PLATELET DERIVED GROWTH FACTOR; PODOCIN; PROTEIN; RNA; STREPTOZOCIN; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; UREA; VASCULOTROPIN; WT1 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG EFFECT; KIDNEY CONCENTRATING CAPACITY; KIDNEY FIBROSIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; PROTEINURIA; TREATMENT RESPONSE; UREA NITROGEN BLOOD LEVEL;

ANIMALS; APOPTOSIS; BIOLOGICAL MARKERS; BLOOD PRESSURE; CHEMOKINES; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FIBROSIS; HUMANS; INJECTIONS, INTRAPERITONEAL; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY; MALE; MICE; MICE, INBRED C57BL; NEPHRECTOMY; NEPHROSCLEROSIS; ORGAN SIZE; PROTEIN C; STREPTOZOCIN; TIME FACTORS;

EID: 84863278229     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2012.04621.x     Document Type: Article

References (34)

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-53.
2. Schoolwerth AC, Engelgau MM, Hostetter TH. A public health action plan is needed for chronic kidney disease. Adv Chronic Kidney Dis 2005; 12: 418-23.
3. Cooper ME. Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet 1998; 352: 213-9.
4. Galkina E, Ley K. Leukocyte recruitment and vascular injury in diabetic nephropathy. J Am Soc Nephrol 2006; 17: 368-77.
5. Goldberg RB. Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. J Clin Endocrinol Metab 2009; 94: 3171-82.
6. Suzuki K, Gabazza EC, Hayashi T, Kamada H, Adachi Y, Taguchi O. Protective role of activated protein C in lung and airway remodeling. Crit Care Med 2004; 32: S262-5.
7. Castellino FJ, Ploplis VA. The protein C pathway and pathologic processes. J Thromb Haemost 2009; 7 (Suppl. 1): 140-5.
8. Matsumoto K, Yano Y, Gabazza EC, Araki R, Bruno NE, Suematsu M, Akatsuka H, Katsuki A, Taguchi O, Adachi Y, Sumida Y. Inverse correlation between activated protein C generation and carotid atherosclerosis in Type 2 diabetic patients. Diabet Med 2007; 24: 1322-8.
9. Isermann B, Vinnikov IA, Madhusudhan T, Herzog S, Kashif M, Blautzik J, Corat MA, Zeier M, Blessing E, Oh J, Gerlitz B, Berg DT, Grinnell BW, Chavakis T, Esmon CT, Weiler H, Bierhaus A, Nawroth PP. Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis. Nat Med 2007; 13: 1349-58.
10. Shimizu S, Gabazza EC, Taguchi O, Yasui H, Taguchi Y, Hayashi T, Ido M, Shimizu T, Nakagaki T, Kobayashi H, Fukudome K, Tsuneyoshi N, D'Alessandro-Gabazza CN, Izumizaki M, Iwase M, Homma I, Adachi Y, Suzuki K. Activated protein C inhibits the expression of platelet-derived growth factor in the lung. Am J Respir Crit Care Med 2003; 167: 1416-26.
11. Lichtnekert J, Rupanagudi KV, Kulkarni OP, Darisipudi MN, Allam R, Anders HJ. Activated protein C attenuates systemic lupus erythematosus and lupus nephritis in MRL-Fas(lpr) mice. J Immunol 2011; 187: 3413-21.
12. Kume E, Doi C, Itagaki S, Nagashima Y, Doi K. Glomerular lesions in unilateral nephrectomized and diabetic (UN-D) mice. J Vet Med Sci 1992; 54: 1085-90.
13. Fioretto P, Mauer M. Histopathology of diabetic nephropathy. Semin Nephrol 2007; 27: 195-207.
14. Brosius FC 3rd, Alpers CE, Bottinger EP, Breyer MD, Coffman TM, Gurley SB, Harris RC, Kakoki M, Kretzler M, Leiter EH, Levi M, McIndoe RA, Sharma K, Smithies O, Susztak K, Takahashi N, Takahashi T. Mouse models of diabetic nephropathy. J Am Soc Nephrol 2009; 20: 2503-12.
15. Kitching AR, Kong YZ, Huang XR, Davenport P, Edgtton KL, Carmeliet P, Holdsworth SR, Tipping PG. Plasminogen activator inhibitor-1 is a significant determinant of renal injury in experimental crescentic glomerulonephritis. J Am Soc Nephrol 2003; 14: 1487-95.
16. Hills CE, Squires PE. TGF-beta1-induced epithelial-to-mesenchymal transition and therapeutic intervention in diabetic nephropathy. Am J Nephrol 2010; 31: 68-74.
17. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol 2008; 214: 199-210.
18. Ziyadeh FN, Wolf G. Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy. Curr Diabetes Rev 2008; 4: 39-45.
19. Langham RG, Kelly DJ, Cox AJ, Thomson NM, Holthofer H, Zaoui P, Pinel N, Cordonnier DJ, Gilbert RE. Proteinuria and the expression of the podocyte slit diaphragm protein, nephrin, in diabetic nephropathy: effects of angiotensin converting enzyme inhibition. Diabetologia 2002; 45: 1572-6.
20. Wolf G, Chen S, Ziyadeh FN. From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy. Diabetes 2005; 54: 1626-34.
21. Lemkes BA, Hermanides J, Devries JH, Holleman F, Meijers JC, Hoekstra JB. Hyperglycemia: a prothrombotic factor? J Thromb Haemost 2010; 8: 1663-9.
22. Jandeleit-Dahm K, Cooper ME. Hypertension and diabetes. Curr Opin Nephrol Hypertens 2002; 11: 221-8.
23. Pickup JC. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 2004; 27: 813-23.
24. Furuta T, Saito T, Ootaka T, Soma J, Obara K, Abe K, Yoshinaga K. The role of macrophages in diabetic glomerulosclerosis. Am J Kidney Dis 1993; 21: 480-5.
25. Viedt C, Orth SR. Monocyte chemoattractant protein-1 (MCP-1) in the kidney: does it more than simply attract monocytes? Nephrol Dial Transplant 2002; 17: 2043-7.
26. Chow FY, Nikolic-Paterson DJ, Ozols E, Atkins RC, Rollin BJ, Tesch GH. Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Kidney Int 2006; 69: 73-80.
27. Jefferson JA, Shankland SJ, Pichler RH. Proteinuria in diabetic kidney disease: a mechanistic viewpoint. Kidney Int 2008; 74: 22-36.
28. Stitt-Cavanagh E, MacLeod L, Kennedy C. The podocyte in diabetic kidney disease. Sci World J 2009; 9: 1127-39.
29. Foster RR. The importance of cellular VEGF bioactivity in the development of glomerular disease. Nephron Exp Nephrol 2009; 113: e8-15.
30. Ziyadeh FN. Different roles for TGF-beta and VEGF in the pathogenesis of the cardinal features of diabetic nephropathy. Diabetes Res Clin Pract 2008; 82 (Suppl. 1): S38-41.
31. Jackson CJ, Xue M, Thompson P, Davey RA, Whitmont K, Smith S, Buisson-Legendre N, Sztynda T, Furphy LJ, Cooper A, Sambrook P, March L. Activated protein C prevents inflammation yet stimulates angiogenesis to promote cutaneous wound healing. Wound Repair Regen 2005; 13: 284-94.
32. Brosius FC 3rd. New insights into the mechanisms of fibrosis and sclerosis in diabetic nephropathy. Rev Endocr Metab Disord 2008; 9: 245-54.
33. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709.
34. Altaweel L, Sweeney D, Cui X, Barochia A, Natanson C, Eichacker PQ. Growing insights into the potential benefits and risks of activated protein C administration in sepsis: a review of preclinical and clinical studies. Biologics 2009; 3: 391-406.